Invesco
CRSP icon

Invesco’s CRISPR Therapeutics CRSP Stock Holding History

Invesco’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.54M Buy
64,989
+872
+1% +$46K ﹤0.01% 2356
2026
Q1 		$3.05M Buy
64,117
+3,321
+5% +$175K ﹤0.01% 2374
2025
Q4 		$3.19M Sell
60,796
-4,531
-7% -$271K ﹤0.01% 2425
2025
Q3 		$4.23M Sell
65,327
-1,321
-2% -$75.8K ﹤0.01% 2303
2025
Q2 		$3.24M Buy
66,648
+38,691
+138% +$1.5M ﹤0.01% 2387
2025
Q1 		$951K Sell
27,957
-5,833
-17% -$247K ﹤0.01% 2854
2024
Q4 		$1.33M Buy
33,790
+2,010
+6% +$94.9K ﹤0.01% 2793
2024
Q3 		$1.49M Sell
31,780
-1,120
-3% -$56.8K ﹤0.01% 2740
2024
Q2 		$1.78M Buy
32,900
+1,332
+4% +$77K ﹤0.01% 2635
2024
Q1 		$2.15M Sell
31,568
-19,616
-38% -$1.4M ﹤0.01% 2636
2023
Q4 		$3.2M Sell
51,184
-84,939
-62% -$4.7M ﹤0.01% 2443
2023
Q3 		$6.18M Buy
136,123
+2,061
+2% +$106K ﹤0.01% 2095
2023
Q2 		$7.53M Sell
134,062
-3,221
-2% -$183K ﹤0.01% 2008
2023
Q1 		$6.21M Buy
137,283
+12,219
+10% +$593K ﹤0.01% 2117
2022
Q4 		$5.08M Sell
125,064
-1,083
-0.9% -$57.5K ﹤0.01% 2238
2022
Q3 		$8.24M Sell
126,147
-1,311
-1% -$95K ﹤0.01% 1923
2022
Q2 		$7.75M Buy
127,458
+9,335
+8% +$549K ﹤0.01% 2018
2022
Q1 		$7.42M Buy
118,123
+26,428
+29% +$1.66M ﹤0.01% 2143
2021
Q4 		$6.95M Sell
91,695
-4,757
-5% -$416K ﹤0.01% 2222
2021
Q3 		$10.8M Sell
96,452
-31,768
-25% -$3.99M ﹤0.01% 1962
2021
Q2 		$20.8M Buy
128,220
+10,438
+9% +$1.27M 0.01% 1595
2021
Q1 		$14.4M Sell
117,782
-187,564
-61% -$28.3M ﹤0.01% 1742
2020
Q4 		$46.8M Buy
305,346
+163,412
+115% +$19.3M 0.01% 1052
2020
Q3 		$11.9M Sell
141,934
-42,578
-23% -$3.78M ﹤0.01% 1571
2020
Q2 		$13.6M Sell
184,512
-5,795
-3% -$339K ﹤0.01% 1467
2020
Q1 		$8.07M Buy
190,307
+56,928
+43% +$2.94M ﹤0.01% 1634
2019
Q4 		$8.12M Buy
133,379
+103,822
+351% +$5.67M ﹤0.01% 1890
2019
Q3 		$1.21M Buy
+29,557
New +$1.41M ﹤0.01% 2891
2018
Q3 		– Sell
-75,075
Closed -$4.41M – 3891
2018
Q2 		$4.41M Buy
+75,075
New +$4.28M ﹤0.01% 2221

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Invesco's CRSP Position: Q2 2026 in Review

Invesco increased its CRISPR Therapeutics (CRSP) stake by 1.4% in Q2 2026, buying an estimated $46K and bringing the position to 64,989 shares worth $3.54M. The position accounts for ﹤0.01% of the portfolio, ranked #2356.

Invesco first reported a position in CRSP in Q2 2018 and has held it in 29 quarters since. The position peaked at $46.8M in Q4 2020. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Invesco held 64,989 shares of CRISPR Therapeutics worth $3.54M as of Q2 2026.
  • Invesco bought 872 CRISPR Therapeutics shares in Q2 2026, an estimated $46K.
  • CRISPR Therapeutics made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #2356 holding.
  • Invesco first reported a position in CRISPR Therapeutics in Q2 2018 and has held it in 29 quarters since.
  • Invesco's CRISPR Therapeutics position peaked at $46.8M in Q4 2020.
  • 522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.